A practical approach for adoption of a hub and spoke model for cell and gene therapies in low- and middle-income countries: framework and case studies.

Publication Year: 2023

DOI:
10.1038/s41434-023-00425-x

PMCID:
PMC10788266

PMID:
37903929

Journal Information

Full Title: Gene Ther

Abbreviation: Gene Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Genetics, Medical

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests OD, DA, DT, MD, AP, and BKT are employees of Novartis Gene Therapies, Inc., and own stock/other equities. SS and MT have received consulting fees from Novartis Gene Therapies, Inc., for this research. SDS has received research grants and consulting fees from Novartis Gene Therapies, Inc., and served as consultant/on an advisory board for Bayer US. ST has received honoraria from Novartis Gene Therapies, Inc. He has also received payment for participation on a BioMarin advisory board and participated in a scientific advisory board meeting for UCB Pharma."

Evidence found in paper:

"Funding This study was funded by Novartis Gene Therapies, Inc."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025